Indofarma Revenue Grows 90%
The state-owned pharmaceutical company, PT Indofarma Tbk recorded a brilliant performance in the first semester of 2021. The issuer with the stock code INAF on the Indonesia Stock Exchange (IDX), posted a 90% yoy growth in revenue to Rp 849.32 billion from the previous Rp 447.29 billion. in the first semester of.
Read More...
